Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.

Hoffman TL, LaBranche CC, Zhang W, Canziani G, Robinson J, Chaiken I, Hoxie JA, Doms RW.

Proc Natl Acad Sci U S A. 1999 May 25;96(11):6359-64.

2.

HIV-1 gp120 V3 loop for structure-based drug design.

Sirois S, Sing T, Chou KC.

Curr Protein Pept Sci. 2005 Oct;6(5):413-22. Review.

PMID:
16248793
3.

HIV coreceptors: from discovery and designation to new paradigms and promise.

Alkhatib G, Berger EA.

Eur J Med Res. 2007 Oct 15;12(9):375-84. Review.

PMID:
17933717
4.

Macrophage activation through CCR5- and CXCR4-mediated gp120-elicited signaling pathways.

Lee C, Liu QH, Tomkowicz B, Yi Y, Freedman BD, Collman RG.

J Leukoc Biol. 2003 Nov;74(5):676-82. Epub 2003 Jul 22. Review.

PMID:
12960231
5.

Molecular mechanisms of HIV entry.

Wilen CB, Tilton JC, Doms RW.

Adv Exp Med Biol. 2012;726:223-42. doi: 10.1007/978-1-4614-0980-9_10. Review.

PMID:
22297516
6.

The role of CD4 in HIV envelope-mediated pathogenesis.

Siliciano RF.

Curr Top Microbiol Immunol. 1996;205:159-79. Review.

PMID:
8575195
7.

Human immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target.

Cammack N.

Antivir Chem Chemother. 1999 Mar;10(2):53-62. Review.

PMID:
10335399
8.

Genetic knockouts suggest a critical role for HIV co-receptors in models of HIV gp120-induced brain injury.

Maung R, Medders KE, Sejbuk NE, Desai MK, Russo R, Kaul M.

J Neuroimmune Pharmacol. 2012 Jun;7(2):306-18. doi: 10.1007/s11481-011-9328-x. Epub 2011 Nov 29. Review.

9.

Human immunodeficiency virus and heparan sulfate: from attachment to entry inhibition.

Connell BJ, Lortat-Jacob H.

Front Immunol. 2013 Nov 20;4:385. doi: 10.3389/fimmu.2013.00385. Review.

Supplemental Content

Support Center